The PI3K inhibitor, taselisib (GDC-0032), has enhanced potency in PIK3CA mutant models through a unique mechanism of action

被引：4
|
作者：
Edgar, Kyle A.
Song, Kyung
Schmidt, Stephen
Kirkpatrick, Don
Phu, Lilian
Nannini, Michelle
Hong, Rebecca
Cheng, Eric
Young, Amy
Sampath, Deepak
Friedman, Lori S.
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-370
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
370
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Treatment of PIK3CA and APC mutant colorectal cancers with dual PI3K/mTOR inhibition.
    Tyler, Foley
    Payne, Susan
    Yeuh, Alexander
    Van DeHey, Dana
    Pasch, Cheri
    Clipson, Linda
    Matkowskyj, Kristina
    Deming, Dustin A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [42] Dual PI3K/mTOR inhibition as a treatment strategy for PIK3CA and APC mutant colorectal cancers
    Payne, Susan
    Foley, Tyler
    Pasch, Cheri
    Yueh, Alexander
    Korkos, Demetra
    Van De Hey, Dana
    Clipson, Linda
    Deming, Dustin
    [J]. CANCER RESEARCH, 2016, 76
  • [43] Expanded biomarker results from a phase I dose escalation study of GDC-0032, a beta isoform-sparing PI3K inhibitor
    Wilson, Timothy R.
    Savage, Heidi
    O'Brien, Carol
    Sanabria, Sandra
    Lin, Ray S.
    Wagle, Marie-Claire
    Yan, Yibing
    Lackner, Mark R.
    Parmar, Hema
    Hsu, Jerry Y.
    Juric, Dejan
    Krop, Ian E.
    Ramanathan, Ramesh K.
    Von Hoff, Daniel D.
    Baselga, Jose
    [J]. CANCER RESEARCH, 2014, 74 (19)
  • [44] PIK3CA and PIK3R1 mutations in cancer: from the mechanism of activation to PI3K targeted therapies
    Rzepecka, Iwona K.
    Tysarowski, Andrzej
    [J]. ONCOLOGY IN CLINICAL PRACTICE, 2024,
  • [45] PIK3CA regulates development of diabetes retinopathy through the PI3K/Akt/mTOR pathway
    Guan, Ruijuan
    Kang, Zefeng
    Li, Ling
    Yan, Xin
    Gao, Tianpeng
    [J]. PLOS ONE, 2024, 19 (01):
  • [46] PIK3CA mutations and response to PI3K and MEK targeted therapies in NSCLC
    Heavey, S.
    Davies, M. A.
    O'Byrne, K. J.
    Gately, K.
    [J]. LUNG CANCER, 2013, 79 : S3 - S3
  • [47] PIK3CA Mutations PREDICT RESPONSE TO PI3K/AKT/mTOR INHIBITORS
    不详
    [J]. CANCER DISCOVERY, 2012, 2 (03) : 205 - 205
  • [48] PI3K expression and PIK3CA mutations are related to colorectal cancer metastases
    Zhu, Yu-Fen
    Yu, Bao-Hua
    Li, Da-Li
    Ke, Hong-Lin
    Guo, Xian-Zhi
    Xiao, Xiu-Ying
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2012, 18 (28) : 3745 - 3751
  • [49] PI3K expression and PIK3CA mutations are related to colorectal cancer metastases
    Yu-Fen Zhu
    [J]. World Journal of Gastroenterology, 2012, (28) : 3745 - 3751
  • [50] Understanding PI3K inhibitor mechanism of action
    Sarah Crunkhorn
    [J]. Nature Reviews Drug Discovery, 2021, 20 (11) : 816 - 816
12345